Atypical Haemolytic Uraemic Syndrome – RDG
- Aims of the Group
- To establish and maintain a registry of all individuals affected by aHUS in the UK
- To provide information to clinicians on the investigation and management of aHUS
- To provide information to affected individuals and their families on aHUS
- To facilitate collaborative research into all aspects of aHUS
- Current Activities
Details of the current activities of the group can be found in the minutes of the RDG meetings and in the annual reports below.
- International Links
The group has links with members of the International Complement Society, the European Complement Network and the European Working Party on Complement Genetics in Renal Disease.
- Patient Support Groups
The National Renal Complement Therapy Centre‘s website has news and information about aHUS and the NHS specialised service.
- Group Members
- Paul Barlow, Professor of Structural Biology, University of Edinburgh
- Terry Cook, Professor of Renal Pathology, Imperial College
- Tim Goodship, Professor of Renal Medicine, Newcastle University
- Claire Harris, Professor, Cardiff University School of Medicine & Head of Complement at GSK, Stevenage, UK
- Sally Johnson, Consultant Paediatric Nephrologist, Newcastle Hospitals NHS Foundation Trust
- David Kavanagh, Senior Lecturer in Nephrology, Newcastle University RDG Lead
- Kevin Marchbank, Lecturer in Applied Immunobiology, Newcastle University
- Paul Morgan, Dean of Medicine, Cardiff University School of Medicine
- Steve Perkins, Professor, Department of Structural and Molecular Biology, University College London
- Matthew Pickering, Professor of Rheumatology, Imperial College
- Len Woodward, aHUSUK Representative
- Anna Richards, Wellcome Intermediate Clinical Training Fellow, University of Edinburgh
- Marie Scully, Consultant Haematologist, University College London Hospitals
- Neil Sheerin, Professor of Nephrology, Newcastle University
- Paul Warwicker, Consultant Nephrologist, East and North Hertfordshire NHS Trust
- Aoife Waters, Consultant Paediatric Nephrologist, Great Ormond Street Hospital
- Disclosure of Conflicts of Interest
Tim Goodship – Fees received by Newcastle University from Alexion Pharmaceuticals (aHUS Advisory Board, UK CI for eculizumab studies, UK CI for aHUS Registry, lectures and seminars). Chair of the Board of Trustees, Kidney Research UK.
Claire Harris – Contract of employment as Head of Complement at GSK, Stevenage, UK.
Matthew Pickering – Fees received from Alexion Pharmaceuticals for invited lectures and funding for pre-clinical studies on experimental complement reagents.
Written by the aHUS Rare Disease Group